कीमोथेरेपी: ओपन एक्सेस
खुला एक्सेस

अमूर्त

Liposome Encapsulated Doxorubicin Citrate (Ledc) as an Alternative Therapeutic Option for Patients with Recurrent Ovarian Cancer Suffering from Doxorubicin-Related Cutaneous Toxicity

Roberto Angioli, Michela Angelucci, Francesco Plotti, Corrado Terranova, Roberto Montera, Patrizio Damiani, Ester Valentina Cafa, Pierluigi Benedetti Panici and Angiolo Gadducci

Introduction: Pegylated liposomal doxorubicin (PLD) is considered to be the single-agent of first choice for patients with recurrent ovarian cancer following paclitaxel/carboplatin-based chemotherapy. However, this drug is associated with a local inflammatory tissue reaction, called palmoplantar erythrodysesthesia (PPE). A new liposomal formulation, known as Liposome Encapsulated Doxorubicin Citrate (LEDC), has been developed in the past decades to limit PPE. In this study we report our experience with LEDC in patients with recurrent ovarian cancer who discontinued doxil due to severe PPE.
Methods: The present retrospective study included 43 patients with recurrent ovarian cancer who were treated with LEDC administered at the dose of 50 mg/mq every 3 weeks until disease progression or unacceptable toxicity. Toxicity was graded according to the National Cancer Institute Common Toxicity Criteria Version 3. Response was graded according to Response Evaluation Criteria in Solid Tumors (RECIST).
Results: A total of 32 patients completed planned 6 cycles of chemotherapy. A complete response was achieved in 6%, partial response in 20%, stable disease in 37% and progression in 9% of patients. No cutaneous toxicity was reported.
Conclusion: LEDC is a well tolerated drug and a valid therapeutic option for patients with ovarian cancer suffering from doxil-related cutaneous toxicity.